$VRTX · Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals reported third quarter 2026 total revenue of $3.44 billion, a 12% increase from the prior-year period, driven by continued cystic fibrosis product performance and growth from newer therapies including CASGEVY, JOURNAVX, and PALSONIFY. The company also raised its full-year 2026 revenue guidance to a range of $13.15 billion to $13.25 billion, up from the prior range of $13.1 billion to $13.2 billion.
The quarter included the closing of Vertex’s acquisition of Crinetics Pharmaceuticals, which the company described as establishing a fourth commercial pillar in rare endocrine diseases. Vertex also highlighted an upcoming PDUFA date for povetacicept in IgA nephropathy on November 30, which it expects could create a fifth commercial franchise in renal medicine. GAAP net income declined to $654 million from $1.1 billion a year earlier, primarily due to compensation and transaction-related expenses tied to the Crinetics acquisition, while non-GAAP net income was $1.2 billion in both periods.
Vertex ended the quarter with $9.8 billion in cash, cash equivalents, and marketable securities, down from $12.3 billion at the end of 2025, reflecting the Crinetics acquisition and share repurchases, partially offset by a $4.5 billion term loan and operating cash flow.